2024-09-19 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals Inc. is a biotechnology company that focuses on the development and commercialization of therapies for serious diseases.

**Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** 180.22% (VRTX) vs. 129.06% (VOO)
* **Outperformance:** VRTX has outperformed the S&P 500 by 51.16%. 
* **Relative Outperformance:** This represents a 81.44% relative outperformance, indicating that VRTX's performance is in the top 81.44% of its historical range compared to the S&P 500. 

**Recent Price Movements:**

* **Closing Price:** $481.83
* **5-Day Moving Average:** $482.0
* **20-Day Moving Average:** $480.96
* **60-Day Moving Average:** $481.92

**Technical Indicators:**

* **RSI:** 50.97 -  RSI is currently in the neutral range, suggesting neither overbought nor oversold conditions.
* **PPO:** 0.17 -  A positive PPO indicates that the price is above the moving averages, suggesting a potential bullish trend.
* **Delta_Previous_Relative_Divergence:** -2.81 - This indicates a recent short-term decline in relative outperformance.
* **Expected Return:** 14.94% - This represents the estimated maximum potential return over the next 5 years based on current investment.

**Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2023-08-02 | 3.55 | 2.49 B$ |
| 2024-08-02 | 3.55 | 2.49 B$ |

The most recent earnings report for Q2 2024 showed an EPS of -13.92, falling short of analysts' expectations. The company attributed the decline to increased investment in research and development activities.  Revenue for the quarter reached $2.65 billion, slightly exceeding expectations.

**Overall Analysis:**

Vertex Pharmaceuticals Inc. has consistently outperformed the S&P 500 over the long term. While recent price action shows a slight decline in relative outperformance, the technical indicators are still positive, suggesting potential for continued growth.  However, it is important to note that the recent earnings report fell short of expectations, highlighting the risks associated with a company heavily invested in research and development. Investors should continue to monitor the company's progress in developing new treatments and watch for any changes in its future guidance. 
